Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …

Simple Summary Breast cancer is the most common cancer among women. It is estimated
that 2.3 million new cases of BC are diagnosed globally each year. Based on mRNA gene …

Cancer classification aims to provide an accurate diagnosis of the disease and prediction of
tumor behavior to facilitate oncologic decision making. Traditional breast cancer …

In recent decades, the increasing interest in the field of immunotherapy has fostered an
intense investigation of the breast cancer (BC) immune microenvironment. In this context …

Breast cancer therapy involves a multidisciplinary approach comprising surgery,
radiotherapy, neoadjuvant and adjuvant therapy. Effective therapy of breast cancer requires …

Simple Summary The dichotomous classification of HER2 status is experiencing a paradigm
change, leading to the identification of the so-called “HER2-low” category. The aim of our …

Breast cancer is a heterogeneous disease that affects one anatomic site, yet is
phenotypically variable. 1, 2 The identification of different biological subtypes occurs …

Despite advances in genomic classification of breast cancer, current clinical tests and
treatment decisions are commonly based on protein level information. Formalin-fixed …

Advances in HER2-targeted therapies have improved the survival of patients with HER2-
positive breast cancer. The standard-of-care treatment for localized disease has been …